It is a normal biological and psychological response to opiate drug use. OxyContin contributed to rapidly increasing overdose deaths. Every year, more people overdose on OxyContin and similar drugs. Purdue Pharma responded to the growing addiction and overdose crisis by changing the drug. As Forbes. Users found themselves switching to other substances or finding ways to work around the changes. They found themselves facing health crises resulting from taking too much of the drug or taking it in combination with other substances like alcohol, sleep aids, or anti-anxiety medications.
OxyContin is still a widely prescribed drug. Many people take it for medical and recreational purposes. Addiction continues to be a problem. Overdose rates continue to rise. A drug that promises relief continues to create problems instead. Luckily today there are resources for recovery. There are options for managing pain and stress without using addictive substances. J Clin Anesth. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. Kalso E. J Pain Symptom Manage.
Trends in opioid consumption in the Nordic countries Eur J Pain. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. Oxycodone Professional Monograph. Tidsskr Nor Laegeforen. A systematic review of oxycodone in the management of cancer pain. Palliat Med. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study.
Sumitani M, Yamada Y. Gan To Kagaku Ryoho. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand J Gastroenterol. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination MoxDuo in the treatment of postoperative pain.
J Opioid Manag. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy R , an extended-release formulation of oxycodone. Postgrad Med. Efficacy and safety of an extended-release oxycodone Remoxy formulation in patients with moderate to severe osteoarthritic pain.
Oxycodone dose-dependently imparts conditioned reinforcing properties to discrete sensory stimuli in rats. Pharmacol Res. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. Ann Pharmacother.
Zacny JP, Gutierrez S. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers. Psychopharmacology Berl. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol. Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life.
Kral LA. Commonsense oxycodone prescribing and safety. Pain Treat Topics. In this article How did the problem with oxycodone evolve? The evidence about oxycodone Oxycodone prescribing in secondary care What lessons can be learnt? References In this article. How did the problem with oxycodone evolve? The international experience Oxycodone was first synthesised in Germany in and became available for use in the United States in The situation in New Zealand Between and , the number of dispensed prescriptions for strong opioids in New Zealand has increased significantly Figure 1.
Addictive potential: oxycodone rates higher than morphine All opioid analgesics including weak opioids are potentially addictive, but the marketing campaign for oxycodone promoted the belief that it had a lower addictive potential than other strong opioids. Renal impairment: use oxycodone with caution Many clinicians have prescribed oxycodone in preference to morphine due to the belief that oxycodone is safer in patients with renal impairment.
Adverse effect profile: similar overall to morphine Overall, oxycodone and morphine have similar adverse event profiles that are consistent with other opioid analgesics. The oxycodone marketing campaign It has been suggested that the high use of oxycodone is partly related to the marketing campaign for OxyContin. Oxycodone prescribing in secondary care Dispensing data shows that in New Zealand, the majority of prescriptions for oxycodone are not being written by General Practitioners.
Emphasise that all opioids have the potential to be addictive and in most circumstances, they are for short-term use only. What lessons can be learnt? Key points for reducing the use of oxycodone: Morphine is the first-line treatment when a strong opioid is indicated for moderate to severe pain; this applies in any setting Oxycodone is not an appropriate analgesic for mild to moderate pain If patients are discharged from hospital with a strong opioid, the prescription should cover a short time period only and the patient should have a treatment plan for tapering use of analgesics Primary care clinicians do not need to repeat a prescription for patients discharged from hospital on a strong opioid The decision to prescribe oxycodone, or any strong opioid, should take into account the predicted net benefits from treatment, weighed up with the risks of adverse effects, misuse and addiction.
Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J ;—6. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev ;— Dobbin M. Pharmaceutical drug misuse in Australia. Aust Prescr ;— Ministry of Health MoH. Pharmaceutical collection. Accessed Jun, Oxycodone: a pharmacological and clinical review. Clin Transl Oncol ;— Does the pharmacology of oxycodone justify its increasing use as an analgesic?
Trends Pharmacol Sci ;— Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model.
Eur J Clin Pharmacol ;—9. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol ;— NZF v Available from: www. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.
Palliat Med ;— Oxycodone: a review of its use in the management of pain. Curr Med Res Opin ;— Kalso E. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health ;—7. Government Accounting Office. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report.
0コメント